FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Humanin

HN / HNG / Humanin G

Longevity & Anti-Aging

Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of mitochondrial DNA, first discovered in 2001 from surviving neurons in Alzheimer's disease brains. It exhibits potent neuroprotective, anti-apoptotic, and cytoprotective properties across multiple organ systems through interactions with IGFBP-3, BAX, and the formyl peptide receptor-like 1 (FPRL1). Research interest has expanded from neurodegeneration to encompass metabolic disease, cardiovascular protection, and aging biology.

작용 메커니즘

Mitochondria-derived micropeptide encoded in the 16S rRNA region. Neuroprotective through binding to IGFBP-3 (blocking apoptosis), activating STAT3 signaling, and modulating BAX-mediated cell death. Also improves insulin sensitivity and reduces amyloid-beta toxicity.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Research protocols are primarily preclinical. Humanin analogs (HNG, HNGF6A) used at 1-4mg/kg in animal models. Human dosing not established. Intranasal and subcutaneous routes studied.

연구 노트

Clinical Research Status

Humanin remains in the preclinical and early translational research phase, with no completed human clinical trials as of current literature. Observational studies have found that circulating humanin levels decline with age and correlate inversely with markers of cognitive decline and metabolic dysfunction. Several humanin analogs with enhanced potency and stability, particularly HNG (S14G-Humanin), have been developed to overcome the native peptide's short half-life and advance toward clinical testing.

Key Published Findings

The original discovery by Bhimori Hashimoto (2001) demonstrated that humanin specifically protected neurons against amyloid-beta toxicity, presenilin mutant-induced apoptosis, and other Alzheimer's-related insults. Subsequent research revealed humanin acts as an insulin sensitizer, reducing hepatic glucose production and improving glucose tolerance in animal models of diabetes. Studies in cardiovascular models show humanin protects against ischemia-reperfusion injury, reduces atherosclerotic plaque formation, and inhibits vascular smooth muscle cell apoptosis.

Safety Profile

As an endogenously produced peptide, humanin is considered to have a favorable safety profile, though systematic toxicology studies in humans have not been conducted. The primary theoretical concern involves its anti-apoptotic properties potentially interfering with tumor suppression mechanisms, though some evidence suggests it may actually enhance certain anti-cancer immune responses. No significant adverse effects have been reported in animal studies at supraphysiological doses, though long-term exposure data remains limited.

Comparison to Related Compounds

Humanin is the founding member of the mitochondrial-derived peptide family, which also includes MOTS-c (a 16-amino acid exercise mimetic peptide) and the SHLPs (Small Humanin-Like Peptides 1-6). Unlike exogenous neuroprotective peptides such as Cerebrolysin or Semax, humanin represents an endogenous protective signal that declines with mitochondrial aging. The analog HNG is approximately 1000-fold more potent than native humanin, making it more practical for research applications.

Community Observations

Interest in humanin within longevity research communities centers on its role as a biomarker and potential therapeutic for mitochondrial aging. Due to extremely limited commercial availability and the early stage of research, human experimentation outside academic settings is rare. The peptide's connection to centenarian genetics (elevated humanin levels correlate with exceptional longevity) has generated significant interest in the anti-aging research community.

반감기

~30-60 minutes

재조성

Sterile saline or bacteriostatic water

보관

건조한 상태

Store at -20C. Sensitive to freeze-thaw cycles.

재조성된 상태

Refrigerate 2-8C. Use within 7 days.

미국 법적 상태

Research chemical (not FDA-approved)

또는 알려진 이름으로

HNHNGHumanin G

자주 묻는 질문

Humanin란 무엇인가요?

Humanin is a 24-amino acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of mitochondrial DNA, first discovered in 2001 from surviving neurons in Alzheimer's disease brains. It exhibits potent neuroprotective, anti-apoptotic, and cytoprotective properties across multiple organ systems through interactions with IGFBP-3, BAX, and the formyl peptide receptor-like 1 (FPRL1). Research interest has expanded from neurodegeneration to encompass metabolic disease, cardiovascular protection, and aging biology.

Humanin는 어떻게 작용하나요?

Mitochondria-derived micropeptide encoded in the 16S rRNA region. Neuroprotective through binding to IGFBP-3 (blocking apoptosis), activating STAT3 signaling, and modulating BAX-mediated cell death. Also improves insulin sensitivity and reduces amyloid-beta toxicity.

Humanin의 미국 규제 현황은 어떤가요?

Research chemical (not FDA-approved)

Humanin의 반감기는 얼마인가요?

~30-60 minutes

Humanin의 다른 이름은 무엇인가요?

HN, HNG, Humanin G

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기